Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

Williams describes depression as the most disabling condition worldwide and a major risk factor for medical disease, now recognized by the American Heart Association as a coronary artery disease risk factor. Using TMS, his lab shows that stimulating the left dorsolateral prefrontal cortex (DLPFC)—a key control region—causes highly time‑locked heart‑rate deceleration via a defined pathway (DLPFC → cingulate → insula → amygdala → nucleus tractus solitarius → vagus → heart). This suggests depression involves dysregulated brain–heart circuitry and impaired top‑down control over autonomic state, rather than simply low serotonin.

Lesion and TMS data show that circuits functionally connected to left DLPFC are antidepressant when excited, while right DLPFC circuits are associated with mania when overactive. In depressed patients, activity in the anterior cingulate (conflict/emotion monitor) tends to precede the DLPFC—subcortical regions drive the “coach.” Effective TMS flips this temporal order so DLPFC leads the cingulate again, restoring cognitive control over intrusive negative content. The magnitude of this re‑timing correlates with antidepressant response.

Standard FDA‑cleared TMS delivers modest stimulation once daily for six weeks with partial response rates. Williams’ SAINT/SNT protocol uses MRI‑guided targeting of each patient’s DLPFC subregion maximally anti‑correlated with the subgenual cingulate, then delivers hippocampal‑rhythm theta‑burst TMS sessions every hour for 10 hours/day over five days (a “cramming” schedule based on spaced‑learning physiology). This amounts to ~5x the conventional dose compressed into a week. In trials, 60–90% of highly treatment‑resistant patients reach full remission, often including those with suicidality, with some maintaining wellness for months to years.

Ketamine, psilocybin, MDMA, ibogaine, and ayahuasca each induce highly plastic states in which traumatic or depressive memories can be re‑experienced and reconsolidated in new ways—akin to an extreme form of exposure and response prevention or cognitive restructuring. However, Williams’ ketamine+naltrexone study shows that blocking opioid receptors abolishes ketamine’s antidepressant effect without changing its dissociative “trip,” disproving the idea that subjective experience alone is sufficient. Psilocybin and SAINT both reduce connectivity between the subgenual cingulate (negative mood) and the default mode network (self), suggesting a convergent circuit‑level mechanism despite very different interventions.

MDMA shows strong, durable effects for PTSD (about two‑thirds achieve clinically significant relief after 1–3 sessions) without evidence of long‑term cognitive harm in controlled or “pure use” cohorts, contradicting earlier flawed neurotoxicity claims. Psilocybin can yield robust, sometimes long‑lasting antidepressant effects in about one‑third to two‑thirds of patients depending on design and treatment‑resistance. Ibogaine, though cardiotoxic in susceptible people, appears uniquely potent for trauma and addiction, producing vivid closed‑eye “life reviews” and moral injury repair in special operations veterans. Ayahuasca (oral DMT + reversible MAOI) has antidepressant and possible anti‑recidivism effects. Williams stresses all of these require rigorous screening, medical oversight, and should not be treated as casual or recreational.